HeartBeam Announces FDA Submission of HeartBeam AIMIGo™ VECG System

Author's Avatar
May 18, 2023

HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D vector electrocardiogram (VECG) platform intended for patient use at home, today announced it has submitted a 510(k) application to the U.S. Food and Drug Administration (FDA) for its HeartBeam AIMIGo™ System.